Benzodiazepine use and multidimensional health burden in severe psychiatric disorders: Impaired quality of life, metabolic comorbidities, and adverse effects in a large cross-sectional study
These findings suggest that BZ use in severe psychiatric disorders may be linked to a substantial multidimensional health burden, including reduced QoL, greater side effect profile, and increased metabolic risk. These results highlight the need for evaluation of long-term BZ use and the promotion of safer alternative treatments.
Authors
- Guillaume B. Fond (ORCID: https://orcid.org/0000-0003-3249-2030)
- Théo Korchia (ORCID: https://orcid.org/0000-0002-6392-9322)
- Vincent Achour
- Mélanie Faugère (ORCID: https://orcid.org/0000-0001-5567-8650)
- Christophe Lançon
- Éloïse Maakaron (ORCID: https://orcid.org/0000-0003-2590-2927)
- Jonathan Gavat
Institutions
- Ceres (US)
- Aix-Marseille Université (FR)
- Hôpital Sainte-Marguerite (FR)
Publication Details
- Journal
- European Psychiatry
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1192/j.eurpsy.2025.10098
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00